Earnings

Merck Signs Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Preclinical Oral KRAS G12D Inhibitor, For $400M Up Front Plus Payments; Company To Record Pre-Tax Charge Of $0.13 Per Share In Q3

Sep 28, 2026 · 06:48 AM ET· updated 44m ago

Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive an upfront payment of $400 million and is eligible to receive

Why It Matters

Merck bought the rights to a new experimental medicine for $400 million. This is a big bet on a drug that could help fight cancer.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MRK148.33

-0.46 (-0.31%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.